An open‐label, non‐randomized, drug‐repurposing study to explore the clinical effects of Angiotensin II Type 1 (AT1) receptor antagonists on anxiety and depression in Parkinson's Disease

Background: The cerebral Renin-Angiotensin System might have a role in anxiety and depression development. Objective: We explored the effects of Angiotensin II Type 1 receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACE-Is) on anxiety and depression in Parkinson’s Disease (PD)....

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Bordet, Sofía, Grasso, Lina, Udovin, Lucas, Chevalier, Guenson, Otero-Losada, Matilde, Capani, Francisco, Pérez-Lloret, Santiago
Formato: Artículo
Lenguaje:Inglés
Publicado: International Parkinson and Movement Disorder Society 2025
Materias:
ENFERMEDAD DE PARKINSON
DEPRESION
ANSIEDAD
ANGIOTENSINA II
Acceso en línea:https://repositorio.uca.edu.ar/handle/123456789/20021
Aporte de:
Repositorio Institucional de la Universidad Católica Argentina (UCA) de Universidad Católica Argentina
id I33-R139-123456789-20021
record_format dspace
spelling I33-R139-123456789-200212025-07-08T05:01:18Z An open‐label, non‐randomized, drug‐repurposing study to explore the clinical effects of Angiotensin II Type 1 (AT1) receptor antagonists on anxiety and depression in Parkinson's Disease Bordet, Sofía Grasso, Lina Udovin, Lucas Chevalier, Guenson Otero-Losada, Matilde Capani, Francisco Pérez-Lloret, Santiago ENFERMEDAD DE PARKINSON DEPRESION ANSIEDAD ANGIOTENSINA II Background: The cerebral Renin-Angiotensin System might have a role in anxiety and depression development. Objective: We explored the effects of Angiotensin II Type 1 receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACE-Is) on anxiety and depression in Parkinson’s Disease (PD). Methods: Four hundred and twenty-three newly diagnosed drug-naïve PD patients were evaluated using the State–Trait Anxiety Inventory (STAI) and Geriatric Depression Scale (GDS-15) tests and were monitored at baseline and for up to 3 years. Results: Twelve patients were treated with ARBs and 42 with ACE-Is. ARB-treated patients had lower anxiety STAI scores than those on ACE-Is or drug-free at baseline (17.2 1.3 vs. 21.3 1.3, or 23.8 0.5, respectively, P = 0.021) and during the follow-up (P < 0.01). Depression scores were unaffected by any of the drugs throughout the study. Conclusion: This small sample of ARB-treated PD patients displayed lower levels of anxiety. Randomized clinical trials are warranted. 2025-07-07T13:52:58Z 2025-07-07T13:52:58Z 2025 Artículo https://repositorio.uca.edu.ar/handle/123456789/20021 10.1002/mdc3.14326 eng Atribución-NoComercial-CompartirIgual 4.0 Internacional http://creativecommons.org/licenses/by-nc-sa/4.0/ application/pdf International Parkinson and Movement Disorder Society Movement Disorders Clinical Practice. 12(5), 2025.
institution Universidad Católica Argentina
institution_str I-33
repository_str R-139
collection Repositorio Institucional de la Universidad Católica Argentina (UCA)
language Inglés
topic ENFERMEDAD DE PARKINSON
DEPRESION
ANSIEDAD
ANGIOTENSINA II
spellingShingle ENFERMEDAD DE PARKINSON
DEPRESION
ANSIEDAD
ANGIOTENSINA II
Bordet, Sofía
Grasso, Lina
Udovin, Lucas
Chevalier, Guenson
Otero-Losada, Matilde
Capani, Francisco
Pérez-Lloret, Santiago
An open‐label, non‐randomized, drug‐repurposing study to explore the clinical effects of Angiotensin II Type 1 (AT1) receptor antagonists on anxiety and depression in Parkinson's Disease
topic_facet ENFERMEDAD DE PARKINSON
DEPRESION
ANSIEDAD
ANGIOTENSINA II
description Background: The cerebral Renin-Angiotensin System might have a role in anxiety and depression development. Objective: We explored the effects of Angiotensin II Type 1 receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACE-Is) on anxiety and depression in Parkinson’s Disease (PD). Methods: Four hundred and twenty-three newly diagnosed drug-naïve PD patients were evaluated using the State–Trait Anxiety Inventory (STAI) and Geriatric Depression Scale (GDS-15) tests and were monitored at baseline and for up to 3 years. Results: Twelve patients were treated with ARBs and 42 with ACE-Is. ARB-treated patients had lower anxiety STAI scores than those on ACE-Is or drug-free at baseline (17.2 1.3 vs. 21.3 1.3, or 23.8 0.5, respectively, P = 0.021) and during the follow-up (P < 0.01). Depression scores were unaffected by any of the drugs throughout the study. Conclusion: This small sample of ARB-treated PD patients displayed lower levels of anxiety. Randomized clinical trials are warranted.
format Artículo
author Bordet, Sofía
Grasso, Lina
Udovin, Lucas
Chevalier, Guenson
Otero-Losada, Matilde
Capani, Francisco
Pérez-Lloret, Santiago
author_facet Bordet, Sofía
Grasso, Lina
Udovin, Lucas
Chevalier, Guenson
Otero-Losada, Matilde
Capani, Francisco
Pérez-Lloret, Santiago
author_sort Bordet, Sofía
title An open‐label, non‐randomized, drug‐repurposing study to explore the clinical effects of Angiotensin II Type 1 (AT1) receptor antagonists on anxiety and depression in Parkinson's Disease
title_short An open‐label, non‐randomized, drug‐repurposing study to explore the clinical effects of Angiotensin II Type 1 (AT1) receptor antagonists on anxiety and depression in Parkinson's Disease
title_full An open‐label, non‐randomized, drug‐repurposing study to explore the clinical effects of Angiotensin II Type 1 (AT1) receptor antagonists on anxiety and depression in Parkinson's Disease
title_fullStr An open‐label, non‐randomized, drug‐repurposing study to explore the clinical effects of Angiotensin II Type 1 (AT1) receptor antagonists on anxiety and depression in Parkinson's Disease
title_full_unstemmed An open‐label, non‐randomized, drug‐repurposing study to explore the clinical effects of Angiotensin II Type 1 (AT1) receptor antagonists on anxiety and depression in Parkinson's Disease
title_sort open‐label, non‐randomized, drug‐repurposing study to explore the clinical effects of angiotensin ii type 1 (at1) receptor antagonists on anxiety and depression in parkinson's disease
publisher International Parkinson and Movement Disorder Society
publishDate 2025
url https://repositorio.uca.edu.ar/handle/123456789/20021
work_keys_str_mv AT bordetsofia anopenlabelnonrandomizeddrugrepurposingstudytoexploretheclinicaleffectsofangiotensiniitype1at1receptorantagonistsonanxietyanddepressioninparkinsonsdisease
AT grassolina anopenlabelnonrandomizeddrugrepurposingstudytoexploretheclinicaleffectsofangiotensiniitype1at1receptorantagonistsonanxietyanddepressioninparkinsonsdisease
AT udovinlucas anopenlabelnonrandomizeddrugrepurposingstudytoexploretheclinicaleffectsofangiotensiniitype1at1receptorantagonistsonanxietyanddepressioninparkinsonsdisease
AT chevalierguenson anopenlabelnonrandomizeddrugrepurposingstudytoexploretheclinicaleffectsofangiotensiniitype1at1receptorantagonistsonanxietyanddepressioninparkinsonsdisease
AT oterolosadamatilde anopenlabelnonrandomizeddrugrepurposingstudytoexploretheclinicaleffectsofangiotensiniitype1at1receptorantagonistsonanxietyanddepressioninparkinsonsdisease
AT capanifrancisco anopenlabelnonrandomizeddrugrepurposingstudytoexploretheclinicaleffectsofangiotensiniitype1at1receptorantagonistsonanxietyanddepressioninparkinsonsdisease
AT perezlloretsantiago anopenlabelnonrandomizeddrugrepurposingstudytoexploretheclinicaleffectsofangiotensiniitype1at1receptorantagonistsonanxietyanddepressioninparkinsonsdisease
AT bordetsofia openlabelnonrandomizeddrugrepurposingstudytoexploretheclinicaleffectsofangiotensiniitype1at1receptorantagonistsonanxietyanddepressioninparkinsonsdisease
AT grassolina openlabelnonrandomizeddrugrepurposingstudytoexploretheclinicaleffectsofangiotensiniitype1at1receptorantagonistsonanxietyanddepressioninparkinsonsdisease
AT udovinlucas openlabelnonrandomizeddrugrepurposingstudytoexploretheclinicaleffectsofangiotensiniitype1at1receptorantagonistsonanxietyanddepressioninparkinsonsdisease
AT chevalierguenson openlabelnonrandomizeddrugrepurposingstudytoexploretheclinicaleffectsofangiotensiniitype1at1receptorantagonistsonanxietyanddepressioninparkinsonsdisease
AT oterolosadamatilde openlabelnonrandomizeddrugrepurposingstudytoexploretheclinicaleffectsofangiotensiniitype1at1receptorantagonistsonanxietyanddepressioninparkinsonsdisease
AT capanifrancisco openlabelnonrandomizeddrugrepurposingstudytoexploretheclinicaleffectsofangiotensiniitype1at1receptorantagonistsonanxietyanddepressioninparkinsonsdisease
AT perezlloretsantiago openlabelnonrandomizeddrugrepurposingstudytoexploretheclinicaleffectsofangiotensiniitype1at1receptorantagonistsonanxietyanddepressioninparkinsonsdisease
_version_ 1845297947733917696

Ejemplares similares